Medtronic Advances AFib Treatment with Promising Data on Next-Generation Pulsed Field Ablation Technologies
SHERIDAN, WYOMING – May 05, 2025 – Medtronic plc (NYSE: MDT) has announced encouraging one-year clinical outcomes for its investigational Affera™ pulsed field ablation (PFA) technologies, reinforcing its strategic leadership in arrhythmia management. The results—revealed at the Heart Rhythm Society 2025 Annual Meeting—highlight the performance of the next-generation Sphere-360™ single-shot PFA catheter and the dual-energy Sphere-9™ catheter in treating patients with paroxysmal and persistent atrial fibrillation (AFib), one of the world’s most prevalent cardiac rhythm disorders.
Sphere-360™ Demonstrates Safety, Efficiency, and Superior Mapping Integration
The Sphere-360 catheter, part of the Affera ecosystem, is engineered as a single-shot PFA mapping and ablation tool designed specifically for paroxysmal AFib. In a European-based, multi-center clinical trial, the technology achieved: